GlassScriptPhysician profile
James R Egner
NPI 1053330993
$10,113.76
in general payments reported to CMS, 2019-2025
48 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $926 · 2021: $1,085 · 2022: $1,535 · 2023: $1,790 · 2024: $2,122 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,910 · Education: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,910.46 |
| Education | $648.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $972.60 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $895.69 | 2019-2025 | Keytruda, Lenvima, Lynparza |
| Janssen Biotech, INC. | $813.69 | 2019-2025 | Darzalex, Erleada, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $790.62 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| Abbvie INC. | $680.27 | 2021-2025 | Venclexta |
| Novartis Pharmaceuticals Corporation | $622.86 | 2019-2025 | |
| Daiichi Sankyo INC. | $605.86 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Pfizer INC. | $600.00 | 2019-2025 | |
| Celgene Corporation | $515.12 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Genzyme Corporation | $437.33 | 2019-2025 | |
| Genentech USA, INC. | $400.27 | 2019-2025 | Alecensa, Rozlytrek, Tecentriq |
| E.R. Squibb & Sons, L.L.C. | $284.52 | 2019-2025 | Opdivo |
| Taiho Oncology, INC. | $262.77 | 2019-2025 | |
| Gilead Sciences, INC. | $217.89 | 2022-2025 | Trodelvy |
| Astellas Pharma US INC | $193.55 | 2023-2024 | Xospata, Vyloy |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $176.55 | 2020-2025 | Nplate, Vectibix, Blincyto |
| Eisai INC. | $172.18 | 2019-2024 | |
| Array Biopharma INC | $166.18 | 2020-2024 | Mektovi, Tukysa, Braftovi |
| Pharmacyclics LLC, An Abbvie Company | $151.76 | 2019-2022 | |
| Seagen INC. | $123.17 | 2023 | Tukysa |
| Beigene USA, INC. | $95.21 | 2021-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $87.48 | 2022-2024 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $80.52 | 2023-2025 | Monjuvi, Pemazyre, Zynyz |
| Emd Serono, INC. | $64.04 | 2023-2024 | Bavencio |
| Alexion Pharmaceuticals, INC. | $62.10 | 2020-2025 | Ultomiris |
| Adaptive Biotechnologies Corporation | $48.61 | 2024-2025 | Clonoseq |
| Genentech, INC. | $43.57 | 2023-2024 | Herceptin, Alecensa, Columvi |
| Regeneron Healthcare Solutions, INC. | $40.46 | 2022-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $39.83 | 2022-2023 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $38.24 | 2019-2021 | |
| Medivation Services LLC | $35.58 | 2025 | |
| Caris Mpi, INC. | $35.25 | 2025 | Mi Cancer Seek |
| G1 Therapeutics, INC. | $34.97 | 2022 | |
| Rigel Pharmaceuticals, INC. | $33.54 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Clovis Oncology, INC. | $32.20 | 2020 | |
| Geron Corporation | $31.61 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $30.79 | 2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $28.29 | 2023 | Monoferric |
| Karyopharm Therapeutics INC. | $26.81 | 2023 | Xpovio |
| Teva Pharmaceuticals USA, INC. | $22.42 | 2024 | Truxima |
| Bayer Healthcare Pharmaceuticals INC. | $17.93 | 2020 | |
| Verastem, INC. | $17.11 | 2020 | |
| Adc Therapeutics America, INC. | $16.22 | 2025 | |
| Servier Pharmaceuticals LLC | $14.94 | 2025 | |
| Beone Medicines USA, INC. | $14.60 | 2025 | Brukinsa |
| Puma Biotechnology, INC. | $13.31 | 2019 | |
| Medtronic USA, INC. | $13.00 | 2019 | |
| Exelixis INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Egner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.